Literature DB >> 24395927

Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload.

Michael R Zile1, Catalin F Baicu, Robert E Stroud, An O Van Laer, Jeffrey A Jones, Risha Patel, Rupak Mukherjee, Francis G Spinale.   

Abstract

BACKGROUND: Although matrix metalloproteinases (MMPs) were initially thought to result primarily in extracellular matrix degradation, certain MMP types, such as membrane type-1 (MT1) MMP, may also be involved in profibrotic cascades through hydrolysis of latency-associated transforming growth factor-binding protein (LTBP-1) and activation of transforming growth factor-dependent profibrotic signaling. The present study tested the hypothesis that MT1-MMP plays a direct role in the matrix remodeling response to a left ventricular (LV) pressure overload (PO) stimulus. METHODS AND
RESULTS: Wild-type (WT) and transgenic mice with cardiac-restricted MT1-MMP overexpression or MT1-MMP reduced expression underwent PO for 4 weeks. PO resulted in a 57% increase in LV mass (no change in LV end diastolic volume, resulting in an increase in the LV mass/volume ratio consistent with concentric remodeling), a 60% increase in MT1-MMP-mediated LTBP-1 hydrolysis and a 190% increase in collagen content in WT mice. Although LV mass was similar among WT, MT1-MMP overexpression, and MT1-MMP reduced expression after PO, significant differences in LV function, MT1-MMP-mediated LTBP-1 hydrolysis, and collagen content occurred. PO in MT1-MMP overexpression increased LTBP-1 hydrolysis (18%), collagen content (60%), and left atrial dimension (19%; indicative of LV diastolic dysfunction) when compared with WT. PO in MT1-MMP reduced expression reduced left atrial dimension (19%), LTBP-1 hydrolysis (40%), and collagen content (32%) when compared with both WT.
CONCLUSIONS: Despite an equivalent PO stimulus and magnitude of LV myocardial growth, altering MT1-MMP levels caused specific matrix-dependent changes in remodeling, thereby demonstrating a mechanistic role in the development of the maladaptive remodeling and myocardial fibrotic response to PO.

Entities:  

Keywords:  hypertrophy; left ventricular; matrix metalloproteinases

Mesh:

Substances:

Year:  2014        PMID: 24395927      PMCID: PMC3961496          DOI: 10.1161/CIRCHEARTFAILURE.113.000984

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  52 in total

1.  Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I.

Authors:  Z Zhou; S S Apte; R Soininen; R Cao; G Y Baaklini; R W Rauser; J Wang; Y Cao; K Tryggvason
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

2.  Myocardial titin and collagen in cardiac diastolic dysfunction: partners in crime.

Authors:  Nazha Hamdani; Walter J Paulus
Journal:  Circulation       Date:  2013-05-24       Impact factor: 29.690

3.  Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures.

Authors:  L M Williams; D L Gibbons; A Gearing; R N Maini; M Feldmann; F M Brennan
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

Review 4.  Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.

Authors:  D E Gomez; D F Alonso; H Yoshiji; U P Thorgeirsson
Journal:  Eur J Cell Biol       Date:  1997-10       Impact factor: 4.492

5.  Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix.

Authors:  Sarah L Dallas; Jennifer L Rosser; Gregory R Mundy; Lynda F Bonewald
Journal:  J Biol Chem       Date:  2002-04-02       Impact factor: 5.157

6.  Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin gamma 2 chain.

Authors:  Naohiko Koshikawa; Tomoko Minegishi; Andrew Sharabi; Vito Quaranta; Motoharu Seiki
Journal:  J Biol Chem       Date:  2004-11-03       Impact factor: 5.157

7.  Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules.

Authors:  E Ohuchi; K Imai; Y Fujii; H Sato; M Seiki; Y Okada
Journal:  J Biol Chem       Date:  1997-01-24       Impact factor: 5.157

8.  Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression.

Authors:  Victoria Polyakova; Stefan Hein; Sawa Kostin; Tibor Ziegelhoeffer; Jutta Schaper
Journal:  J Am Coll Cardiol       Date:  2004-10-19       Impact factor: 24.094

Review 9.  Integrating the myocardial matrix into heart failure recognition and management.

Authors:  Francis G Spinale; Michael R Zile
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

10.  Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle.

Authors:  Michael R Zile; Catalin F Baicu; William H Gaasch
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

View more
  10 in total

1.  Secreted protein acidic and rich in cysteine facilitates age-related cardiac inflammation and macrophage M1 polarization.

Authors:  Hiroe Toba; Lisandra E de Castro Brás; Catalin F Baicu; Michael R Zile; Merry L Lindsey; Amy D Bradshaw
Journal:  Am J Physiol Cell Physiol       Date:  2015-04-15       Impact factor: 4.249

2.  Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.

Authors:  Michael R Zile; Pardeep S Jhund; Catalin F Baicu; Brian L Claggett; Burkert Pieske; Adriaan A Voors; Margaret F Prescott; Victor Shi; Martin Lefkowitz; John J V McMurray; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2016-01       Impact factor: 8.790

3.  Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice.

Authors:  Juozas A Zavadzkas; Robert E Stroud; Shenikqua Bouges; Rupak Mukherjee; Jeffrey R Jones; Risha K Patel; Paul J McDermott; Francis G Spinale
Journal:  Circ Res       Date:  2014-03-17       Impact factor: 17.367

4.  Pressure and Temperature Effects on the Activity and Structure of the Catalytic Domain of Human MT1-MMP.

Authors:  Elena Decaneto; Saba Suladze; Christopher Rosin; Martina Havenith; Wolfgang Lubitz; Roland Winter
Journal:  Biophys J       Date:  2015-12-01       Impact factor: 4.033

Review 5.  From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure With Preserved Ejection Fraction Paradigm Revisited.

Authors:  Walter J Paulus; Michael R Zile
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

Review 6.  Systems biology-opportunities and challenges: the application of proteomics to study the cardiovascular extracellular matrix.

Authors:  Javier Barallobre-Barreiro; Marc Lynch; Xiaoke Yin; Manuel Mayr
Journal:  Cardiovasc Res       Date:  2016-09-15       Impact factor: 10.787

7.  Guidelines for measuring cardiac physiology in mice.

Authors:  Merry L Lindsey; Zamaneh Kassiri; Jitka A I Virag; Lisandra E de Castro Brás; Marielle Scherrer-Crosbie
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-01-05       Impact factor: 4.733

8.  Matrix metalloproteinase-14 is a biomarker of angiogenic activity in proliferative diabetic retinopathy.

Authors:  Ahmed M Abu El-Asrar; Ghulam Mohammad; Eef Allegaert; Ajmal Ahmad; Mohammad Mairaj Siddiquei; Kaiser Alam; Priscilla W Gikandi; Gert De Hertogh; Ghislain Opdenakker
Journal:  Mol Vis       Date:  2018-05-18       Impact factor: 2.367

9.  Intrauterine Programming of Diabetes Induced Cardiac Embryopathy.

Authors:  Rolanda Lister; Alyssa Chamberlain; Francine Einstein; Bingruo Wu; DeYou Zheng; Bin Zhou
Journal:  Diabetes Obes Int J       Date:  2019-05-06

Review 10.  Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling.

Authors:  Margaux A Horn; Andrew W Trafford
Journal:  J Mol Cell Cardiol       Date:  2015-11-11       Impact factor: 5.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.